Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment. There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.
Study Type
OBSERVATIONAL
Enrollment
160
Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.
Vestre Viken HF, Drammen
Drammen, Norway
RECRUITINGDiakonhjemmet hospital
Oslo, Norway
RECRUITINGP1NP level 3 months after glucocorticoid termination
P1NP in a blood sample
Time frame: september 2024 til december 2025
P1NP level 6 months after glucocorticoid termination
P1NP in a blood sample
Time frame: september 2024 til december 2025
CTX1 level 3 and 6 months after glucocorticoid termination
CTX1 in a blood sample
Time frame: september 2024 til december 2025
P1NP and CTX1 dynamic until 6 months after treatment of inflammation without glucocorticoids
P1NP and CTX1 in a blood sample
Time frame: september 2024 til december 2025
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.